Mizoribine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Mizoribine
Accession Number
DB12617
Type
Small Molecule
Groups
Investigational
Description

Mizoribine has been investigated for the treatment of Rheumatoid Arthritis.

Structure
Thumb
Synonyms
  • BREDININ
Categories
UNII
4JR41A10VP
CAS number
50924-49-7
Weight
Average: 259.216
Monoisotopic: 259.080435163
Chemical Formula
C9H13N3O6
InChI Key
HZQDCMWJEBCWBR-UUOKFMHZSA-N
InChI
InChI=1S/C9H13N3O6/c10-7(16)4-8(17)12(2-11-4)9-6(15)5(14)3(1-13)18-9/h2-3,5-6,9,13-15,17H,1H2,(H2,10,16)/t3-,5-,6-,9-/m1/s1
IUPAC Name
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxy-1H-imidazole-4-carboxamide
SMILES
NC(=O)C1=C(O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Mizoribine.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Mizoribine is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Mizoribine is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Mizoribine is combined with 5-androstenedione.Experimental, Illicit
AcebutololMizoribine may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Mizoribine is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Mizoribine is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolMizoribine may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcepromazineThe serum concentration of Acepromazine can be increased when it is combined with Mizoribine.Approved, Vet Approved
AceprometazineThe serum concentration of Aceprometazine can be increased when it is combined with Mizoribine.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Mizoribine.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Mizoribine.Experimental
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Mizoribine is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Mizoribine.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Mizoribine is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Mizoribine is combined with Alendronic acid.Approved
AlimemazineThe serum concentration of Alimemazine can be increased when it is combined with Mizoribine.Approved, Vet Approved
AliskirenMizoribine may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Mizoribine is combined with Alminoprofen.Experimental
AlprenololMizoribine may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Mizoribine.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Amcinonide.Approved
AmilorideMizoribine may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Mizoribine is combined with Aminosalicylic Acid.Approved
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Mizoribine.Approved, Investigational, Withdrawn
AncrodMizoribine may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Mizoribine.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Mizoribine is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Mizoribine is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Mizoribine.Investigational
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Mizoribine is combined with Anthrax immune globulin human.Approved
AntipyrineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Antipyrine.Approved, Investigational
Antithrombin III humanMizoribine may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Antrafenine.Approved
ApixabanMizoribine may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Mizoribine is combined with Apocynin.Investigational
ApramycinMizoribine may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Mizoribine.Approved, Investigational
ArbekacinMizoribine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinMizoribine may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanMizoribine may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololMizoribine may decrease the antihypertensive activities of Arotinolol.Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Mizoribine is combined with Artemether.Approved
AsenapineMizoribine may decrease the antihypertensive activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Atamestane.Investigational
AtenololMizoribine may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Mizoribine.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Mizoribine.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Mizoribine is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Mizoribine.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Mizoribine.Investigational
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of adverse effects can be increased when Mizoribine is combined with Bacillus calmette-guerin substrain connaught live antigen.Approved, Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of adverse effects can be increased when Mizoribine is combined with Bacillus calmette-guerin substrain tice live antigen.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Balsalazide.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Mizoribine.Investigational
BecaplerminMizoribine may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololMizoribine may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinMizoribine may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Mizoribine is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Mizoribine is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Mizoribine.Approved
BenorilateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Mizoribine.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Mizoribine.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Mizoribine.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Betamethasone.Approved, Vet Approved
BetaxololMizoribine may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Mizoribine.Approved, Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Mizoribine.Approved, Investigational
BevantololMizoribine may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Mizoribine is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Mizoribine.Approved, Investigational
BisoprololMizoribine may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinMizoribine may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BL-1020The serum concentration of BL-1020 can be increased when it is combined with Mizoribine.Investigational
BopindololMizoribine may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Mizoribine is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Mizoribine.Investigational
BucindololMizoribine may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Mizoribine.Approved
BufexamacThe risk or severity of adverse effects can be increased when Mizoribine is combined with Bufexamac.Approved, Experimental
BufuralolMizoribine may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Mizoribine.Approved
BupranololMizoribine may decrease the antihypertensive activities of Bupranolol.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mizoribine.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Mizoribine.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Mizoribine.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Mizoribine is combined with Candoxatril.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when Mizoribine is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Mizoribine is combined with Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Mizoribine is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Mizoribine.Approved
CarprofenThe risk or severity of adverse effects can be increased when Mizoribine is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololMizoribine may decrease the antihypertensive activities of Carteolol.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Mizoribine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Mizoribine is combined with Celecoxib.Approved, Investigational
CeliprololMizoribine may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinMizoribine may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Mizoribine.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mizoribine.Approved, Vet Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Mizoribine is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorproethazineThe serum concentration of Chlorproethazine can be increased when it is combined with Mizoribine.Experimental
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Mizoribine.Approved, Investigational, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Mizoribine.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Mizoribine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Mizoribine is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Mizoribine is combined with Cimicoxib.Investigational
CinoxacinMizoribine may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CisplatinThe risk or severity of adverse effects can be increased when Mizoribine is combined with Cisplatin.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Mizoribine is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Mizoribine is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Mizoribine.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Mizoribine.Vet Approved
CloranololMizoribine may decrease the antihypertensive activities of Cloranolol.Experimental
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Mizoribine is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
ColesevelamColesevelam can cause a decrease in the absorption of Mizoribine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Mizoribine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Cortisone acetate.Approved, Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Mizoribine is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Mizoribine.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Mizoribine.Experimental
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Mizoribine.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Mizoribine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Mizoribine.Experimental
Dabigatran etexilateMizoribine may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinMizoribine may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidMizoribine may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapsoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Dapsone.Approved, Investigational
DarexabanMizoribine may increase the anticoagulant activities of Darexaban.Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Mizoribine is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Mizoribine is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Mizoribine is combined with Delapril.Investigational
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Mizoribine.Approved
DesipramineMizoribine may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinMizoribine may increase the anticoagulant activities of Desirudin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Mizoribine.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Mizoribine is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Mizoribine.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Mizoribine is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Mizoribine.Approved, Investigational
DextranMizoribine may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinMizoribine may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Mizoribine is combined with Dibotermin alfa.Approved, Investigational
DicoumarolMizoribine may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Mizoribine is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Difluprednate.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Mizoribine.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Mizoribine.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Mizoribine.Approved
DihydrostreptomycinMizoribine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Mizoribine.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Mizoribine.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Mizoribine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mizoribine.Approved, Investigational
DrospirenoneMizoribine may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Mizoribine is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Mizoribine.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Mizoribine.Investigational
Edetic AcidMizoribine may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanMizoribine may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Mizoribine is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Mizoribine is combined with Enalaprilat.Approved
EnoxacinMizoribine may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinMizoribine may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Mizoribine.Experimental
EpanololMizoribine may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Mizoribine.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Mizoribine.Experimental
EplerenoneMizoribine may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Mizoribine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Mizoribine.Approved
EquileninThe risk or severity of adverse effects can be increased when Mizoribine is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Mizoribine is combined with Equilin.Approved
EsatenololMizoribine may decrease the antihypertensive activities of Esatenolol.Experimental
EsmololMizoribine may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Mizoribine.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Mizoribine is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Ethenzamide.Experimental
Ethyl biscoumacetateMizoribine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Mizoribine is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Mizoribine is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Mizoribine.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Mizoribine is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Mizoribine.Investigational, Nutraceutical
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Mizoribine.Approved
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Mizoribine.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Mizoribine.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Mizoribine.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Mizoribine.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Feprazone.Experimental
Ferulic acidMizoribine may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Mizoribine.Approved, Investigational
FingolimodMizoribine may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinMizoribine may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Mizoribine.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fludrocortisone.Approved, Investigational
FluindioneMizoribine may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineMizoribine may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Mizoribine.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Mizoribine is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fluorometholone.Approved, Investigational
FluphenazineThe serum concentration of Fluphenazine can be increased when it is combined with Mizoribine.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Mizoribine.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Mizoribine is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Mizoribine.Approved, Nutraceutical, Vet Approved
FondaparinuxMizoribine may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Mizoribine.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Formestane.Approved, Investigational, Withdrawn
FramycetinMizoribine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
G17DTThe risk or severity of adverse effects can be increased when Mizoribine is combined with G17DT.Investigational
GabexateMizoribine may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinMizoribine may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinMizoribine may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemcitabineThe risk or severity of adverse effects can be increased when Gemcitabine is combined with Mizoribine.Approved
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Mizoribine.Approved, Withdrawn
GemifloxacinMizoribine may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinMizoribine may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinMizoribine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AMizoribine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GI-5005The risk or severity of adverse effects can be increased when Mizoribine is combined with GI-5005.Investigational
GinsengThe risk or severity of adverse effects can be increased when Mizoribine is combined with Ginseng.Approved, Investigational, Nutraceutical
GitoformateGitoformate may decrease the cardiotoxic activities of Mizoribine.Experimental
GrepafloxacinMizoribine may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Mizoribine is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Mizoribine is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Mizoribine is combined with HE3286.Investigational
HeparinMizoribine may increase the anticoagulant activities of Heparin.Approved, Investigational
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Mizoribine is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Higenamine.Investigational
Human rabies virus immune globulinThe risk or severity of adverse effects can be increased when Mizoribine is combined with Human rabies virus immune globulin.Approved
HydralazineMizoribine may decrease the antihypertensive activities of Hydralazine.Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Mizoribine.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Hydrocortisone butyrate.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Mizoribine.Approved, Investigational
Hygromycin BMizoribine may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Mizoribine.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Mizoribine.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Mizoribine is combined with Icosapent.Approved, Nutraceutical
IdraparinuxMizoribine may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Mizoribine.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Mizoribine is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Mizoribine.Approved
IndenololMizoribine may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Mizoribine.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Mizoribine is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Mizoribine.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Mizoribine is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Mizoribine is combined with INGN 225.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Mizoribine.Approved, Investigational
IrinotecanThe risk or severity of adverse effects can be increased when Irinotecan is combined with Mizoribine.Approved, Investigational
IsepamicinMizoribine may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Mizoribine.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Mizoribine is combined with Istaroxime.Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Mizoribine is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated).Approved
KanamycinMizoribine may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Mizoribine.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Mizoribine is combined with Ketoprofen.Approved, Vet Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Mizoribine.Experimental
LandiololMizoribine may decrease the antihypertensive activities of Landiolol.Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Mizoribine.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Leflunomide.Approved, Investigational
LepirudinMizoribine may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanMizoribine may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololMizoribine may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololMizoribine may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinMizoribine may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Mizoribine.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Mizoribine is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Mizoribine.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Mizoribine.Experimental
LomefloxacinMizoribine may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Mizoribine is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Mizoribine is combined with Lornoxicam.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Mizoribine is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Mizoribine.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Mizoribine.Approved, Investigational
LumefantrineThe risk or severity of QTc prolongation can be increased when Mizoribine is combined with Lumefantrine.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Mizoribine is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Mizoribine.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Mizoribine.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Mizoribine is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Mizoribine is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mizoribine is combined with Mefenamic acid.Approved
MelagatranMizoribine may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Mizoribine is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Mizoribine is combined with Meloxicam.Approved, Vet Approved
MepindololMizoribine may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Mesalazine.Approved
MesoridazineThe serum concentration of Mesoridazine can be increased when it is combined with Mizoribine.Approved, Investigational
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Mizoribine.Approved, Investigational, Withdrawn
MethimazoleThe risk or severity of adverse effects can be increased when Mizoribine is combined with Methimazole.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Mizoribine.Approved
MethotrimeprazineThe serum concentration of Methotrimeprazine can be increased when it is combined with Mizoribine.Approved, Investigational
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mizoribine.Approved
Methylene blueThe serum concentration of Methylene blue can be increased when it is combined with Mizoribine.Approved, Investigational
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Mizoribine.Approved, Vet Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Mizoribine.Experimental
MetipranololMizoribine may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Mizoribine.Approved
MicronomicinMizoribine may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Mizoribine.Approved, Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Mizoribine.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Mizoribine is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Mometasone.Approved, Vet Approved
MoricizineThe serum concentration of Moricizine can be increased when it is combined with Mizoribine.Approved, Investigational, Withdrawn
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Mizoribine.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Mizoribine.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Mizoribine.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Nabumetone.Approved
NadololMizoribine may decrease the antihypertensive activities of Nadolol.Approved
NadroparinMizoribine may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatMizoribine may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Mizoribine.Approved
Nalidixic AcidMizoribine may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Mizoribine is combined with Natalizumab.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Mizoribine is combined with NCX 1022.Investigational
NeamineMizoribine may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololMizoribine may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinMizoribine may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NepafenacThe risk or severity of adverse effects can be increased when Mizoribine is combined with Nepafenac.Approved, Investigational
NetilmicinMizoribine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Mizoribine is combined with Niflumic Acid.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Mizoribine.Investigational
NorfloxacinMizoribine may increase the neuroexcitatory activities of Norfloxacin.Approved
OcrelizumabOcrelizumab may increase the immunosuppressive activities of Mizoribine.Approved, Investigational
OfloxacinMizoribine may increase the neuroexcitatory activities of Ofloxacin.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Mizoribine.Experimental, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mizoribine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Mizoribine.Approved
OlsalazineMizoribine may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Mizoribine is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Mizoribine is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Mizoribine.Vet Approved
OtamixabanMizoribine may increase the anticoagulant activities of Otamixaban.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Mizoribine.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Mizoribine is combined with Oxaprozin.Approved
Oxolinic acidMizoribine may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololMizoribine may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Mizoribine.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mizoribine.Approved, Vet Approved
PalmidrolThe risk or severity of adverse effects can be increased when Mizoribine is combined with Palmidrol.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Mizoribine is combined with Parecoxib.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Parthenolide.Approved, Investigational
PazufloxacinMizoribine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinMizoribine may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololMizoribine may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateMizoribine may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateMizoribine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerazineThe serum concentration of Perazine can be increased when it is combined with Mizoribine.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Mizoribine is combined with Perindopril.Approved
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Mizoribine.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Mizoribine.Experimental
PhenindioneMizoribine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonMizoribine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Phenylbutazone.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Mizoribine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mizoribine.Approved, Investigational
PindololMizoribine may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidMizoribine may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Mizoribine.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Mizoribine.Approved, Investigational
Piromidic acidMizoribine may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Mizoribine is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Mizoribine is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Mizoribine is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorMizoribine may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinMizoribine may decrease the excretion rate of Plazomicin which could result in a higher serum level.Approved, Investigational
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Mizoribine.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Pomalidomide.Approved
Potassium CitrateMizoribine may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololMizoribine may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Mizoribine.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Mizoribine is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Mizoribine.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Mizoribine can be increased when it is combined with Probenecid.Approved, Investigational
ProchlorperazineThe risk or severity of QTc prolongation can be increased when Mizoribine is combined with Prochlorperazine.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Mizoribine is combined with Proglumetacin.Experimental
PromazineThe serum concentration of Promazine can be increased when it is combined with Mizoribine.Approved, Vet Approved
PromethazineThe risk or severity of QTc prolongation can be increased when Mizoribine is combined with Promethazine.Approved, Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Mizoribine.Approved, Investigational
PropericiazineThe serum concentration of Propericiazine can be increased when it is combined with Mizoribine.Approved, Investigational
PropiopromazineThe serum concentration of Propiopromazine can be increased when it is combined with Mizoribine.Vet Approved
PropyphenazoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Proquazone.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Mizoribine.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Mizoribine.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Mizoribine.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Mizoribine.Vet Approved
Protein CMizoribine may increase the anticoagulant activities of Protein C.Approved
Protein S humanMizoribine may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeMizoribine may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinMizoribine may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Mizoribine.Investigational
PuromycinMizoribine may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Mizoribine is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Mizoribine.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Mizoribine is combined with Rabies virus inactivated antigen, A.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Mizoribine.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Mizoribine is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Mizoribine is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinMizoribine may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinMizoribine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Rimexolone.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Mizoribine is combined with Rindopepimut.Investigational
RisedronateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Risedronate.Approved, Investigational
RivaroxabanMizoribine may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Mizoribine is combined with Rofecoxib.Approved, Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Mizoribine.Approved
RosoxacinMizoribine may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Rubella virus vaccine.Approved, Investigational
RufloxacinMizoribine may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Mizoribine.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Mizoribine.Approved
Salmonella typhi ty2 vi polysaccharide antigenThe risk or severity of adverse effects can be increased when Mizoribine is combined with Salmonella typhi ty2 vi polysaccharide antigen.Approved
Salmonella typhi Ty21a live antigenThe risk or severity of adverse effects can be increased when Mizoribine is combined with Salmonella typhi ty21a live antigen.Approved
SalsalateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Mizoribine.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Mizoribine.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Mizoribine.Approved, Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Mizoribine is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Mizoribine.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Mizoribine.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Mizoribine is combined with Serrapeptase.Investigational
SisomicinMizoribine may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinMizoribine may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
SotalolMizoribine may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinMizoribine may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Mizoribine is combined with Spirapril.Approved
SRP 299The risk or severity of adverse effects can be increased when Mizoribine is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Mizoribine.Investigational
StreptomycinMizoribine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Sulfasalazine.Approved
SulodexideMizoribine may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Mizoribine.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Mizoribine is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Suxibuzone.Experimental
TacrolimusTacrolimus may increase the immunosuppressive activities of Mizoribine.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Mizoribine.Approved
TalinololMizoribine may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Mizoribine.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Mizoribine.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Mizoribine.Approved
TecemotideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Tecemotide.Investigational
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Mizoribine.Approved, Investigational
TemafloxacinMizoribine may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Mizoribine is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Mizoribine is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Mizoribine is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Mizoribine is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Mizoribine.Vet Approved
TerbutalineMizoribine may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Mizoribine.Approved
TertatololMizoribine may decrease the antihypertensive activities of Tertatolol.Experimental
TetrandrineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Tetrandrine.Experimental
TG4010The risk or severity of adverse effects can be increased when Mizoribine is combined with TG4010.Investigational
ThiazinamThe serum concentration of Thiazinam can be increased when it is combined with Mizoribine.Experimental
ThiethylperazineThe serum concentration of Thiethylperazine can be increased when it is combined with Mizoribine.Withdrawn
ThioproperazineThe serum concentration of Thioproperazine can be increased when it is combined with Mizoribine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Mizoribine.Approved, Withdrawn
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Mizoribine is combined with Tiaprofenic acid.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Mizoribine is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololMizoribine may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Mizoribine is combined with Tixocortol.Approved, Withdrawn
TobramycinMizoribine may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TofacitinibMizoribine may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Mizoribine is combined with Tolmetin.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Mizoribine.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Mizoribine is combined with Trandolapril.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Mizoribine.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Mizoribine.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Mizoribine.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Triamcinolone.Approved, Vet Approved
TriamtereneMizoribine may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Mizoribine.Approved, Vet Approved
TrifluoperazineThe serum concentration of Trifluoperazine can be increased when it is combined with Mizoribine.Approved, Investigational
TriflupromazineThe serum concentration of Triflupromazine can be increased when it is combined with Mizoribine.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Mizoribine.Investigational
TrovafloxacinMizoribine may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinMizoribine may increase the anticoagulant activities of Troxerutin.Investigational
Typhoid VaccineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Typhoid Vaccine.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Mizoribine is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Mizoribine.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Mizoribine is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Mizoribine.Approved, Investigational
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Mizoribine is combined with Varicella Zoster Vaccine (Live/Attenuated).Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Mizoribine.Approved
WarfarinMizoribine may increase the anticoagulant activities of Warfarin.Approved
XimelagatranMizoribine may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Yellow Fever VaccineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Yellow Fever Vaccine.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Mizoribine.Approved, Investigational
ZidovudineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Zidovudine.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Mizoribine.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Mizoribine is combined with Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Mizoribine.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0041934
PubChem Compound
104762
PubChem Substance
347828830
ChemSpider
94571
BindingDB
68669
ChEBI
31858
ChEMBL
CHEMBL245019
HET
MZR
Wikipedia
Mizoribine
PDB Entries
3b1n

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingTreatmentRheumatoid Arthritis1
3Active Not RecruitingTreatmentGlomerulonephritis minimal lesion1
3Active Not RecruitingTreatmentNephritis, Lupus1
3CompletedTreatmentRheumatoid Arthritis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility36.1 mg/mLALOGPS
logP-2.3ALOGPS
logP-2ChemAxon
logS-0.86ALOGPS
pKa (Strongest Acidic)8.19ChemAxon
pKa (Strongest Basic)2.77ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area151.06 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity55.55 m3·mol-1ChemAxon
Polarizability23.58 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1-ribosyl-imidazolecarboxamides. These are organic compounds containing the imidazole ring linked to a ribose ring through a 1-2 bond.
Kingdom
Organic compounds
Super Class
Nucleosides, nucleotides, and analogues
Class
Imidazole ribonucleosides and ribonucleotides
Sub Class
1-ribosyl-imidazolecarboxamides
Direct Parent
1-ribosyl-imidazolecarboxamides
Alternative Parents
Glycosylamines / Pentoses / 2-heteroaryl carboxamides / Carbonylimidazoles / N-substituted imidazoles / Vinylogous amides / Vinylogous acids / Tetrahydrofurans / Heteroaromatic compounds / Secondary alcohols
show 8 more
Substituents
1-ribosyl-imidazolecarboxamide / Glycosyl compound / N-glycosyl compound / Pentose monosaccharide / 2-heteroaryl carboxamide / Imidazole-4-carbonyl group / N-substituted imidazole / Monosaccharide / Azole / Tetrahydrofuran
show 21 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 17:14 / Updated on August 02, 2018 06:41